Pipeline Review for Histone Deacetylase 3, H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Histone Deacetylase 3 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis.

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 2, 4 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

This report outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons to Buy

  1. Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  2. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  3. Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
  4. Identify the use of drugs for target identification and drug repurposing
  5. Identify potential new clients or partners in the target demographic
  6. Develop strategic initiatives by understanding the focus areas of leading companies
  7. Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  8. Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape
  9. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Overview
  • Therapeutics Development
  • Therapeutics Assessment
  • Companies Involved in Therapeutics Development
  • Drug Profiles
  • Dormant Products
  • Discontinued Products
  • Product Development Milestones
  • Appendix

Companies Mentioned

  • 4D Pharma Plc
  • 4SC AG
  • Chipscreen Biosciences Ltd
  • Curis Inc
  • Kdac Therapeutics Inc
  • Medivir AB
  • Merck & Co Inc
  • Oceanyx Pharmaceuticals Inc
  • OnKure Inc
  • Shuttle Pharmaceuticals Inc
  • Syndax Pharmaceuticals Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hg0qhj

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900